Andrew Obenshain, President and CEO of bluebird bio, Inc., completed a sale of 34,780 shares of common stock on September 30, 2024. The shares were sold at a price of $0.5253 per share, resulting in a total transaction value of $18,269.93. Following the sale, Obenshain holds a total of 375,218 shares in the company. The transaction was executed directly and is part of the company's recent activities in the stock market.

Andrew Obenshain, President and CEO of bluebird bio, Inc., completed a sale of 34,780 shares of common stock on September 30, 2024. The shares were sold at a price of $0.5253 per share, resulting in a total transaction value of $18,269.93. Following the sale, Obenshain holds a total of 375,218 shares in the company. The transaction was executed directly and is part of the company's recent activities in the stock market.